MedTrace Logo

Cholecalciferol on Hemodialysis Patients

NCT03602430 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2019-01-09

No results posted yet for this study

Summary

* Screening the prevalence of vitamin D deficiency among Egyptian hemodialysis patients on a single center (Ain Shams University hospital).
* Assessing the effect of the native type of vitamin D (Cholecalciferol) on replenishing its deficiency via extra-renal vitamin D receptors (VDR), among Egyptian hemodialysis patients.
* Assessing the effect of cholecalciferol on vascular calcification among Egyptian hemodialysis patients.
* Assessing the effect of cholecalciferol on Blood pressure, parathyroid hormone.

Conditions

  • Hemodialysis Complication
  • Vitamin D Deficiency
  • Vascular Calcification

Interventions

DRUG

Cholecalciferol

Native vitamin D dose of 200IU to be given once per month to hemodialysis patients

DRUG

Placebo

A Placebo ampule will be given to hemodialysis patients once per month with their standard treatment for 3 months period. Same color, odor and size, only without the active constituent.

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-01
Primary Completion
2018-09-15
Completion
2018-09-28

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03602430 on ClinicalTrials.gov